×
About 123,980 results

The mechanism of radiotherapy for lung adenocarcinoma in promoting protein SIRT6-mediat...
https://doi.org/10.1177/03946320221130727
International Journal of Immunopathology and Pharmacology; Wang J, Sheng Z et. al.

Sep 30th, 2022 - Lung cancer has the fastest increase in morbidity and mortality, and is one of the most threatening malignant tumors to human health and life. Both radiotherapy and targeted therapy are typical treatments after lung cancer surgery. Radiotherapy is a means of locally killing cancer lesions, and it plays an important role in the entire management of lung cancer. Gefitinib is one of the most commo...

Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512290
Drug Design, Development and Therapy; Xu M, Fan R et. al.

Sep 30th, 2022 - Currently, the treatment for ocular neovascular diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. Although it can preserve vision, repeated injections are an invasive treatment modality, leading to serious complications and reducing patient adherenc...

Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the Firs...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510372
Pathology Oncology Research : POR; Stukaite-Ruibiene E, Norvilas R et. al.

Sep 30th, 2022 - Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, however, it could benefit from treatment with tyrosine kinase inhibitors (TKI). NUP214::ABL1 fusion is detected in 6% of T-cell acute lymphoblastic leukemia (T-ALL), and is very rare in B-ALL. We present a case of adolescent with B-ALL and a cryptic NU...

BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeti...
https://doi.org/10.1080/15384047.2022.2125748
Cancer Biology & Therapy; Ma L, Wang J et. al.

Sep 29th, 2022 - Acute myeloid leukemia (AML) is a highly cancerous and aggressive hematologic disease with elevated levels of drug resistance and relapse resulting in high mortality. Recently, bromodomains and extra-terminal (BET) protein inhibitors have been extensively researched in hematological tumors as potential anticancer agents. MZ1 is a novel BET inhibitor that mediates selective proteins degradation ...

Overcoming chemoresistance in glioblastoma by fluvastatin via prenylation-dependent inh...
https://doi.org/10.1177/09603271221125934
Human & Experimental Toxicology; Long C, Yuan L et. al.

Sep 29th, 2022 - The resistance of glioblastoma to chemotherapy remains a significant clinical problem. Targeting alternative pathways such as protein prenylation is known to be effective against many cancers. Fluvastatin is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl- CoA (HMG-CoA) reductase, thereby inhibits prenylation. We demonstrate that fluvastatin alone effectively inhibits proliferation...

The effect of A1 and A2 reactive astrocyte expression on hydrocephalus shunt failure.
https://doi.org/10.1186/s12987-022-00367-3
Fluids and Barriers of the CNS; Khodadadei F, Arshad R et. al.

Sep 29th, 2022 - The composition of tissue obstructing neuroprosthetic devices is largely composed of inflammatory cells with a significant astrocyte component. In a first-of-its-kind study, we profile the astrocyte phenotypes present on hydrocephalus shunts. qPCR and RNA in-situ hybridization were used to quantify pro-inflammatory (A1) and anti-inflammatory (A2) reactive astrocyte phenotypes by analyzing C3 an...

Establishment and characteristics of GWH04, a new primary human glioblastoma cell line.
https://doi.org/10.3892/ijo.2022.5429
International Journal of Oncology; Cheng F, Wan X et. al.

Sep 29th, 2022 - Glioblastoma multiforme (GBM) is a common and fatal disease of the central nervous system. GBM cell lines are fundamental tools used in GBM research. The establishment of novel continuous GBM cell lines with clear genetic backgrounds could facilitate the exploration of molecular mechanisms and the screening and evaluation of antitumor drugs in GBM studies. In the present study, a novel primary ...

Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative stress i...
https://doi.org/10.3892/or.2022.8417
Oncology Reports; Wang T, Liu J et. al.

Sep 29th, 2022 - Gomisin A (GA) is an effective component of Schisandra. The crude extracts of Schisandra chinensis and its active ingredients have been shown to inhibit multidrug resistance in tumour cells. Reactive oxygen species (ROS) have different roles in cancer and may contribute to therapy resistance. The human ovarian cancer (OC) cell lines SKOV3 and A2780, and a mouse model of OC, were used in the pre...

Subconjunctival Lymphatics Respond to VEGFC and Anti-Metabolites in Rabbit and Mouse Eyes.
https://doi.org/10.1167/iovs.63.10.16
Investigative Ophthalmology & Visual Science; Lee JY, Wu J et. al.

Sep 28th, 2022 - To characterize and pharmacologically influence subconjunctival lymphatics in rabbit and mouse eyes. Rabbits received subconjunctival injections of trypan blue or fixable fluorescent dextrans. Bleb-related outflow pathways were quantified. Immunofluorescence for vessel-specific markers (lymphatics [podoplanin and LYVE-1] and blood vessels [CD31]) were performed in native rabbit conjunctiva and ...

AML-119 The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use ...
https://doi.org/10.1016/S2152-2650(22)01223-X
Clinical Lymphoma, Myeloma & Leukemia; DiNardo C, Pratz K et. al.

Sep 28th, 2022 - In VIALE-A (NCT02993523) and VIALE-C (NCT03069352), Ven+azacitidine (Aza) and low-dose cytarabine (LDAC), respectively, improved outcomes in pts with intensive chemotherapy (IC)-ineligble newly diagnosed AML. To explore outcomes in pts with G-CSFu. VIALE-A/C, dosing and treatment schedule were previously described. G-CSFu was given per institutional practice. Pts who achieved complete remission...

AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Show...
https://doi.org/10.1016/S2152-2650(22)01257-5
Clinical Lymphoma, Myeloma & Leukemia; Daver N, Montesinos P et. al.

Sep 28th, 2022 - Pivekimab sunirine (PVEK, IMGN632) is a first-in-class ADC comprising a CD123 high-affinity antibody, a cleavable linker, and an IGN (indolinobenzodiazepine pseudodimer) payload. PVEK with azacitidine (AZA) and venetoclax (VEN) is a novel triplet that has demonstrated anti-leukemia activity in relapsed/refractory AML patients. Evaluate the anti-leukemia activity in genetic subgroups of AML and ...

AML-522 Outcomes of Patients Treated With Venetoclax-Based Combination Therapy in Acute...
https://doi.org/10.1016/S2152-2650(22)01311-8
Clinical Lymphoma, Myeloma & Leukemia; Ashraf B, Jeon-Slaughter H et. al.

Sep 28th, 2022 - The outcomes of older patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy remain poor. Addition of venetoclax (ven) to hypomethylating agents (HMA) or low dose cytarabine (LoDAC) has become the standard of care based on the VIALE-A and VIALE-C trials. We investigated outcomes of patients treated with ven-based therapy in both newly-diagnosed and R/R settings. Patien...

AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients ...
https://doi.org/10.1016/S2152-2650(22)01268-X
Clinical Lymphoma, Myeloma & Leukemia; Abuasab T, Alvarado Y et. al.

Sep 28th, 2022 - ASTX727 is an oral formulation of the fixed-dose combination of decitabine and cedazuridine (100 mg/35 mg). To investigate whether a total oral regimen of ASTX727+venetoclax (ven) is feasible and safe. Pts ≥18 with relapsed/refractory AML (R/R) or pts with AML aged ≥75 or 18-74 unfit for intensive chemotherapy (frontline; FL) were eligible. Other eligibility criteria included adequate renal and...

CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid...
https://doi.org/10.1016/S2152-2650(22)01388-X
Clinical Lymphoma, Myeloma & Leukemia; Hughes TP, Cortes JE et. al.

Sep 28th, 2022 - In CML-CP, the BCR::ABL1 T315I mutation confers resistance to previously approved ATP-competitive tyrosine kinase inhibitors (TKIs), except ponatinib and olverembatinib. In a previous analysis of the phase I, dose-escalation trial X2101, asciminib-a BCR::ABL1 inhibitor that binds to the ABL myristoyl pocket-demonstrated efficacy and a favorable safety profile in heavily pretreated patients with...

MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Up...
https://doi.org/10.1016/S2152-2650(22)01462-8
Clinical Lymphoma, Myeloma & Leukemia; Pemmaraju N, Kuykendall A et. al.

Sep 28th, 2022 - Polycythemia vera (PV) patients are routinely treated with periodic therapeutic phlebotomy (TP) alone or combined with cytoreductive therapy to maintain hematocrit (HCT) <45% and reduce the incidence of thrombosis. TP may not adequately control HCT and results in iron deficiency. Rusfertide, a hepcidin mimetic, eliminates phlebotomy requirements and improves iron deficiency. We examined the imp...

MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus I...
https://doi.org/10.1016/S2152-2650(22)01570-1
Clinical Lymphoma, Myeloma & Leukemia; Ito R, Eyre TA et. al.

Sep 28th, 2022 - Covalent Bruton's Tyrosine Kinase (BTK) inhibitors (BTKi) have transformed the management of relapsed mantle cell lymphoma (MCL), but many patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that inhibits both wild type and C481-mutated BTK with equal low nM potency. Determine whether pirtobrutinib is superior to investigator's choice ...

c-Met Signaling as a Therapeutic Target in Head and Neck Cancer.
https://doi.org/10.1097/PPO.0000000000000619
Cancer Journal (Sudbury, Mass.); Centuori SM, Bauman JE

Sep 28th, 2022 - Despite a dearth of activating driver mutations in head and neck squamous cell carcinoma (HNSCC), aberrant activation of the oncogenes, epidermal growth factor receptor (EGFR), and c-Met is near-universal in human papillomavirus (HPV)-negative disease. Although EGFR activation drove the successful development of the anti-EGFR monoclonal antibody cetuximab in HNSCC, no c-Met-targeting therapy ha...

PI3K Inhibition for Squamous Cell Head and Neck Carcinoma.
https://doi.org/10.1097/PPO.0000000000000618
Cancer Journal (Sudbury, Mass.); Desilets A, Soulières D

Sep 28th, 2022 - The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with unfavorable risk-benefit ratios in molecularly unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, shows promising effic...

The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for H...
https://doi.org/10.1097/PPO.0000000000000617
Cancer Journal (Sudbury, Mass.); Adkins D, Ley J et. al.

Sep 28th, 2022 - Preclinical data support investigation of selective CDK4/6 inhibition as a therapeutic strategy for human papillomavirus (HPV)-unrelated head and neck squamous cell carcinoma (HNSCC). Phase 1 clinical trials established the feasibility of combining palbociclib with cetuximab in patients with recurrent or metastatic HNSCC. Nonrandomized phase II trials showed that palbociclib plus cetuximab resu...

Mitotic Checkpoints and the Role of WEE1 Inhibition in Head and Neck Squamous Cell Carc...
https://doi.org/10.1097/PPO.0000000000000613
Cancer Journal (Sudbury, Mass.); Khan SN, Swiecicki PL et. al.

Sep 28th, 2022 - The WEE1 kinase family plays a crucial role in cell cycle regulation and DNA damage response pathways in malignant cells. Inhibition of WEE1 effectively overrides G2 cell cycle arrest and results in the accumulation of extensive DNA damage within dividing cells, potentiating mitotic catastrophe and cell death. As such, the development of WEE1 inhibitors as antineoplastic therapeutics has gained...